Second allogeneic hematopoietic stem cell ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC).
Auteur(s) :
Yafour, Nabil [Auteur]
Couturier, Marie-Anne [Auteur]
Azarnoush, Saba [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Girault, Stephane [Auteur]
Hermet, Eric [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Masouridi-Levrat, Stavroula [Auteur]
Schmidt, Aline [Auteur]
Université d'Angers [UA]
Michallet, Mauricette [Auteur]
Etancelin, Pascaline [Auteur]
Guillaume, Thierry [Auteur]
Malard, Florent [Auteur]
Sirvent, Anne [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Poire, Xavier [Auteur]
Couturier, Marie-Anne [Auteur]
Azarnoush, Saba [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Girault, Stephane [Auteur]
Hermet, Eric [Auteur]
Université d'Auvergne - Clermont-Ferrand I [UdA]
Masouridi-Levrat, Stavroula [Auteur]
Schmidt, Aline [Auteur]
Université d'Angers [UA]
Michallet, Mauricette [Auteur]
Etancelin, Pascaline [Auteur]
Guillaume, Thierry [Auteur]
Malard, Florent [Auteur]
Sirvent, Anne [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Poire, Xavier [Auteur]
Titre de la revue :
Bulletin du Cancer
Nom court de la revue :
Bull. Cancer
Numéro :
106
Pagination :
S40-S51
Date de publication :
2019-01
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological ...
Lire la suite >Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological diseases. A second allo-HSCT is a valuable therapeutic option to salvage those situations. During the 8th annual harmonization workshops of the french Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines on feasibility, indications, donor choice and conditioning in the case of a second allo-HSCT. In case of relapse, a second allo-HSCT with reduced intensity or non-myeloablative conditioning is a reasonable option, particularly in patients with a good performance status (Karnofsky/Lansky>80%), low co-morbidity score (EBMT score</=3), a longer remission duration after the first allo-HSCT (>6 months), and who present low disease burden at the time of second allo-HSCT. Matched related donors tend to be associated with better outcomes. In the presence of graft dysfunction (primary and secondary graft rejection), an immunoablative conditioning regimen is recommended. A donor change remains a valid option, especially in the absence of graft-versus-host disease after the first allo-HSCT.Lire moins >
Lire la suite >Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological diseases. A second allo-HSCT is a valuable therapeutic option to salvage those situations. During the 8th annual harmonization workshops of the french Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines on feasibility, indications, donor choice and conditioning in the case of a second allo-HSCT. In case of relapse, a second allo-HSCT with reduced intensity or non-myeloablative conditioning is a reasonable option, particularly in patients with a good performance status (Karnofsky/Lansky>80%), low co-morbidity score (EBMT score</=3), a longer remission duration after the first allo-HSCT (>6 months), and who present low disease burden at the time of second allo-HSCT. Matched related donors tend to be associated with better outcomes. In the presence of graft dysfunction (primary and secondary graft rejection), an immunoablative conditioning regimen is recommended. A donor change remains a valid option, especially in the absence of graft-versus-host disease after the first allo-HSCT.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Date de dépôt :
2019-03-01T14:07:49Z
2024-01-23T09:03:45Z
2024-01-23T09:03:45Z